JASPER + PROMPT Interventions for Autism
(BLOOM Trial)
Trial Summary
What is the purpose of this trial?
In this project, the investigator will test the effect of augmenting an evidence based joint attention intervention (JASPER) with a motor-sound system intervention (PROMPT) compared to JASPER only on speech and language outcomes. The investigator will model change over a year to determine the percentage of children who cross the hurdle from single words to word combinations by Kindergarten. The proposed research will foster the understanding of the mechanisms underlying speech heterogeneity in ASD, thereby ultimately contributing to the development of more personalized, efficacious interventions. Upon qualification to the study (after entry assessments), the child will be randomized to receive JASPER alone (play-based intervention) or JASPER plus PROMPT (both play-based and speech-based interventions). The active intervention will last for 12 weeks, 60 minute sessions twice a week. There are assessments scheduled at entry (6.5 hours), end of study (exit-2.5 hours), 3 month follow up (2 hours), and when the child turns 6 years of age (2 hours). The total time commitment per participant is 37 hours.
Will I have to stop taking my current medications?
The trial requires that participants have stable medication over the past 6 months, which suggests you should not change your current medications.
What data supports the effectiveness of the JASPER and PROMPT treatments for autism?
Research shows that JASPER, which focuses on joint attention and symbolic play, can improve language skills and play diversity in children with autism. Studies found that children receiving JASPER showed greater expressive language gains and improved joint attention quality compared to control groups.12345
Is the JASPER + PROMPT intervention safe for humans?
How is the JASPER treatment for autism different from other treatments?
JASPER is unique because it focuses specifically on improving joint attention (the ability to share focus on an object or event with another person) and symbolic play (using objects to represent other things) in young children with autism, which are areas often overlooked in other treatments. This approach has shown significant improvements in language development and social interactions compared to control groups.12359
Research Team
Eligibility Criteria
The BLOOM trial is for children aged 48-66 months with Autism Spectrum Disorder who are minimally verbal, using less than 20 functional words. They must have walked by 24 months, have a nonverbal mental age over 12 months, and been in early intervention or preschool for at least three months. Children with severe disabilities like deafness, blindness, cerebral palsy or certain genetic disorders associated with ASD are not eligible.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive JASPER alone or JASPER plus PROMPT interventions, 60-minute sessions twice a week
Exit Assessment
Exit assessments including ELSA Language Sample, PLS-5, ESCS, BOSCC, and EEG
Follow-up
Participants are monitored for language outcomes at 3 months post-exit and when the child turns 6 years of age
Treatment Details
Interventions
- JASPER (Behavioral Intervention)
- PROMPT (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
Dr. Thomas Rando
University of California, Los Angeles
Chief Medical Officer since 2023
MD from UCLA
Amir Naiberg
University of California, Los Angeles
Chief Executive Officer since 2024
JD from UCLA
National Institutes of Health (NIH)
Collaborator
Dr. Jeanne Marrazzo
National Institutes of Health (NIH)
Chief Medical Officer
MD from University of California, Los Angeles
Dr. Jay Bhattacharya
National Institutes of Health (NIH)
Chief Executive Officer
MD, PhD from Stanford University